Nonalcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023

Nonalcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023

Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.

NASH is most common in patients who are overweight or obese and other risk factors include diabetes, high cholesterol, high triglycerides, poor diet, metabolic syndrome, polycystic ovary syndrome, sleep apnea, underactive thyroid (hypothyroidism).

The most common symptoms of moderate NASH include weakness, fatigue, loss of appetite, unexplained weight loss. Other advanced symptoms include yellowing of skin, bruising and bleeding, swelling of legs and feet (edema), enlarged liver or enlarged spleen, enlarged, spider-like blood vessels under your skin.

Diagnosis of NASH include blood tests, imaging tests (abdominal ultrasound and CT scan), liver stiffness tests (Fibroscan and magnetic resonance elastography) and liver biopsy.

NASH has no specific medical treatments, taking some steps can help prevent further damage like maintaining a moderate weight, and if this involves losing weight, healthy diet with low amounts of processed foods and fats, limiting or avoiding alcohol. The treatment may include medications and possibly surgery. Patients with NASH who develop liver cancer or liver failure may require a transplant.

There are currently several clinical trials underway for potential treatments for NASH. These include trials testing medications that target specific aspects of the disease, such as inflammation or insulin resistance, as well as more general trials testing treatments that aim to improve overall liver function. Many of these trials are still in the early stages, but some have already shown promising results.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Nonalcoholic Steatohepatitis (NASH) treatment such as Belapectin, Cotadutide, IVA337 and others. Key players involved in the development of therapies to treat Nonalcoholic Steatohepatitis (NASH) are AstraZeneca, Galectin Therapeutics Inc, Intercept Pharmaceuticals, Inventiva Pharma, PharmaKing and others. One drug is under late-stage Pre-Registration and six drugs are in Phase III clinical trials and some other drugs are under Phase II, Phase I, preclinical and discovery stages of development.

In November 2022, Inventiva secured a new patent expanding the IP protection of its lead product candidate lanifibranor in the US and Inventiva and in September 2022, Sino Biopharm announced licensing and collaboration agreement to develop and commercialize lanifibranor in greater China.

Report Highlights

Global Insight Service's, Nonalcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023 report provides an overview of the Non-alcoholic steatohepatitis pipeline drugs. This report covers detailed insights on Nonalcoholic Steatohepatitis (NASH) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Nonalcoholic Steatohepatitis (NASH) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.